Navigation Links
Transposagen Announces Exclusive License with Charles River Laboratories for p53 and Bcrp TGEM™ Knockout Rat Models
Date:10/13/2010

LEXINGTON, Ky., Oct. 13 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc. (Transposagen), the worldwide leader in genetically modified rats, has announced today that it has entered into an exclusive marketing and distribution agreement with Charles River Laboratories, a leading global provider of research models and services.

The license includes two of Transposagen's high-value TGEM™ Knockout Rat Models, one rat line contains a mutation in the p53 gene, the most studied tumor suppressor, and one rat line contains a mutation in the Bcrp gene, encoding an important drug transporter. The p53 gene is the gene most commonly mutated in many human cancers. The p53 TGEM™ Knockout Rat Model recapitulates human cancers and is the only fully phenotyped p53 knockout rat model, now available with complete tumor spectrum and survival data.  

"Our p53 and Bcrp TGEM™  Knockout Rat Models, developed with our academic collaborators at the Hubrecht Institute in the Netherlands, are the first of their kind in the world," said Dr. Eric Ostertag, the President and CEO of Transposagen. "For the p53 TGEM™ Knockout Rat Model in particular, we have years of phenotyping data showing that this research model faithfully produces a wide variety of tumors. Add this to the outstanding breeding standards and quality control offered by our partner, Charles River Laboratories, and customers can be certain that they are getting a quality research model."

These two unique TGEM™ Knockout Rat Models will enhance Charles River's ability to provide its global clients with unique solutions in the drug development process from target validation to toxicology and carcinogenicity testing. Dr. Iva Morse, Corporate Vice President, Global Research Model Services at Charles River, commented, "Charles River is extremely pleased to offer knockout rat models to our clients for the first time by partnering with Transposagen Biop
'/>"/>

SOURCE Transposagen Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MKS Instruments Announces Third Quarter 2010 Earnings Conference Call
2. OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
3. Highland Capital Management Announces 100% Ownership of American HomePatient, Completes Successful Public to Private Transition For Leading Provider of Home Respiratory Therapy
4. Boston Scientific Announces Global Launch of Journey™ Guidewire
5. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
6. CORRECTED - Akorn, Inc. Announces Date Change for Third Quarter 2010 Earnings Release and Conference Call
7. Prime Therapeutics Announces URAC Accreditation
8. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
9. Cellectis bioresearch Announces Establishment of Subsidiary in the US
10. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
11. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... SAN FRANCISCO , June 2, 2015  Nektar ... Texas MD Anderson Cancer Center today announced a research ... evaluate NKTR-214, a CD122-biased cytokine designed to preferentially stimulate ... cells found naturally in the body.  CD122, which is ... a key signaling receptor that is known to increase ...
(Date:6/2/2015)... , June 2, 2015 Northstar ... first television and multi-media commercial advertisement, which it ... to promote SNORenz®, the company,s top selling product. ... the company,s past success with television advertising. Previous ... but this, more modern version takes an entertainment-oriented ...
(Date:6/2/2015)... und MADRID , ... Mündliche Präsentation (Abstract   10503), vorgestellt ... Clinical Oncology    PharmaMar teilt ... ( Janssen) Daten der multizentrischen Phase-3-Studie ... Verbesserung beim progressionsfreien Überleben (progression-free survival, PFS) ...
Breaking Medicine Technology:Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 2Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 3Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 4Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 5Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 6Northstar releases its direct response multi-media ad designed to be used in national television advertising campaigns 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 3PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 4PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 5PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 6
... Ltd. (NYSE Amex: CPD ) announced that ... (Sun) have been extended until January 28, 2012 but ... which was originally set to expire in January 2010, ... and is being extended for an additional 1 year ...
... Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its ... with the Securities and Exchange Commission.  As a result, the ... 2010 Form 10-K to enable its securities to continue trading ... is currently working on preparing and filing its quarterly reports ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 2Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 2K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 4K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 6K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 7K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 8
(Date:6/2/2015)... a popular online store selling celebrity inspired fashion products, ... dresses. The company carries more than 1000 styles of ... a wide variety of summer events like wedding and ... quality trendy special occasion dresses and accessories. ... and cotton. Their products feature a wide range of ...
(Date:6/2/2015)... June 02, 2015 First Choice ... emergency rooms in the United States, named Kenneth Alan ... – Jones Road facility. , “We are pleased ... Houston-Jones Road facility,” said Dr. James M. Muzzarelli, Executive ... Dr. Totz received his undergraduate degree from St. Edwards ...
(Date:6/2/2015)... 2015 Thermi, formerly ThermiAesthetics, a ... successfully transitioned into its new company headquarters in ... company’s continued rapid worldwide expansion and houses the ... 25 Thermi employees, including those of the warehousing, ... “As one of the fastest growing aesthetic companies ...
(Date:6/2/2015)... MA (PRWEB) June 02, 2015 Join us ... Anniversary Awareness Walk in Honor of Rhonda Martin , who ... members have since dedicated their resources to raising awareness and ... seeks to raise awareness in hopes that there will be ... , All are welcome and encouraged to join the ...
(Date:6/1/2015)... 2015 The National Association of ... as a 2015-2016 inductee into its VIP Woman of ... distinction for leadership in business. NAPW is the nation’s ... than 700,000 members and over 200 operating Local Chapters. ... honor,” said NAPW President Star Jones. “Job satisfaction is ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Kenneth Alan Totz as New Medical Director of Houston – Jones Road Facility 2Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2
... Results of two new studies suggest that low-dose estrogen ... experiencing menopausal hot flushes and bleeding. The June issue ... as effective as high-dose estrogen in treating menopausal symptoms. ... irregular bleeding.// , ...
... brain imaging techniques, scientists have indicated the patterns in ... to be stored or deleted. The study was done ... (MIT) and reported to the American Association for the ... ,The researchers coupled a number of different brain parts ...
... Australian researchers have identified a gene which allows the ... drugs.Plasmodium,is a single-celled organism which is transmitted to ... historically evaded control efforts by building resistance to virtually ... is hoped that the new discovery will lead to ...
... treat nausea, and research at the University of Sydney ... studies have shown that the active ingredients in ginger ... ingredient of chilli peppers and capsicum, a known pain ... the body called the vanilloid receptor, which sits on ...
... the hair loss associated with drug treatment for cancer. ,This ... a frequent side effect of cancer therapy and is often ... lives.// ,Currently, there is no effective way to stop ... attempt to minimise hair loss is to fit patients with ...
... researchers at Peterson Medical College, a strategy was developed ... Immunodeficiency Virus (HIV) out of dormancy in the cellular ... Samoan rainforest tree, and appears to stimulate the virus, ... body's immune system to detect and attack it.// ...
Cached Medicine News:Health News:An effective pain killer, 2Health News:Breakthrough in cancer therapy 2Health News:Prostratin- Drug to eradicate HIV 2
Biocryl™ Acrylic Foldable Lens....
The STAAR ELASTIMIDE lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
... The Bausch & Lomb UV-Absorbing, Silicone Posterior ... for primary implantation for the visual correction ... age or older in whom the cataractous ... extraction methods. This device is intended to ...
... lenses are manufactured using the ... Perspex CQ UV PMMA material ... and single piece lenses. Unioptic ... both nonphaco and phaco styles. ...
Medicine Products: